We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Diagnostic Test Detects Three Respiratory Viruses Simultaneously

By Labmedica staff writers
Posted on 17 Jan 2008
A real-time, molecular diagnostic assay simultaneously detects and differentiates influenza A virus, influenza B virus, and respiratory syncytial virus (RSV) from a single specimen.

Called the ProFlu+ assay, it uses real-time polymerase chain reaction (PCR) technology, is simple to use, and easily integrates into existing lab workflow. More...
Real-time technology provides distinct advantages over other molecular diagnostic techniques such as microbeads and microarrays because little hands-on time is required, risk of amplicon contamination is eliminated, equipment cost is relatively low, and inducement concerns are minimized.

The accuracy of the ProFlu+ assay was confirmed in a multi-site clinical study that compared results to traditional viral culture. A total of 826 patient samples were prospectively tested, and the assay demonstrated an overall clinical sensitivity and specificity of 98% and 83%, respectively. The decreased specificity was the result of the ProFlu+ assay detecting more positive samples than cultures. Further testing by genetic sequencing determined that 87 of the 103 samples that were positive by ProFlu+ but negative by culture were likely to have been true-positives

Prodesse, Inc., (Waukesha, WI, USA) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA; Rockville, MD, USA) to market the ProFlu+ assay.

"We are convinced that we made the right choice choosing real-time PCR as our core technology platform,” said Tom Shannon, CEO of Prodesse. "Laboratorians are telling us that the big box multiplex systems are cumbersome and more appropriate for epidemiological, not clinical, applications. ProFlu+ is the first in a lineup of real-time respiratory assays that we are in the process of clearing. All of these will use a common internal control so that a single nucleic acid extraction can be used with multiple assays. Our Pro hMPV+ for detection of human metapneumovirus is currently in clinical trials, and two additional products will shortly begin clinical trials: ProParaflu+, a multiplex assay for differentiating parainfluenza viruses and our first enteric product, ProGastro Cd for Clostridium difficile.

Prodesse focuses on the development, manufacture, and distribution of cost-effective, easy-to-use reagents for infectious disease agents.


Related Links:
Prodesse
U.S. Food and Drug Administration

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.